NEX-0039732 is under clinical development by Nxera Pharma and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NEX-0039732’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NEX-0039732 overview

HTL-0039732 is under development for the treatment of microsatellite stable3 colorectal, gastroesophageal, head and neck squamous cell carcinoma, metastatic castrate resistant prostate cancer, pancreatic cancer, lung cancer, bladder cancer, mesothelioma, cervical cancer, renal cancer, sarcoma and pheochromocytoma. It acts by targeting EP4. The drug candidate is administered through oral route and is being developed based on STAR (Stabilized Receptor) technology. 

Nxera Pharma overview

Nxera Pharma, formerly Sosei Group Corp, is a biopharmaceutical company that develops drugs by using a proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. Its medical products include ultibro, seebri, enerzair, breezhaler, pivlaz and oravi. The company’s in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist and PAR2 mAb. Nxera Pharma partnered pipeline program comprises CCR6 antagonist, muscarinic M4 agonist, MC4 antagonist, muscarinic M1 agonist, dual muscarinic M1 and M4 agonists, GPR35 agonist, CXCR4 mAb, PAR2 peptide, targeted GPCR degradation, ion channels, OX2 agonist and mGlu5 NAM, among others. The company operates in Japan, South Korea, Ireland and the UK. Nxera Pharma is headquartered in Chiyoda-ku, Tokyo, Japan.

For a complete picture of NEX-0039732’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.